Skip to main content
. 2017 Oct 17;17:691. doi: 10.1186/s12885-017-3679-5

Fig. 3.

Fig. 3

Acceptability curve of the Markov model comparing the strategies XELOX and XELOX plus bevacizumab used in the first line in the treatment of patients with metastatic colorectal cancer